相关实验视频

Updated: Jan 13, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

"IgA血管炎研究":一个横截面队列的演变成为一个试验准备的队列队列

Chloe E C Williams^1,2, Julien Marro², Andrew J Chetwynd³

¹Department of Nephrology, Royal Liverpool and Broadgreen University Hospital Trusts, Liverpool, UK.

Rheumatology advances in practice

|October 28, 2025

概括

这项研究建立了IgA血管炎 (IgAV) 试验准备的队列,以预防功能衰竭. 在IgAV患者的早期炎需要及时的儿科科干预,并影响住院治疗.

科学领域:

儿科脏病学儿科脏病学
免疫学免疫学免疫学
类风湿病学类风湿病学

背景情况:

IgA血管炎 (IgAV) 是一种全身性血管炎,可能导致严重的并发症.
炎是IgAV的一个重大问题,但指导其管理的证据有限.
开发一个试验准备的队列对于推进研究和改善IgAV相关功能衰竭的干预措施至关重要.

研究的目的:

描述IgA血管炎 (IgAV) 的单中心队列研究的建立和演变.
为未来的临床试验创建一个试验准备的框架,旨在预防IgAV患者功能衰竭.
提供有关IgAV.儿童炎自然史和风险因素的见解.

主要方法:

建立了一个单中心,横截面的队列研究,演变成一个试验准备的框架.
从被诊断为IgAV的儿童收集社会人口统计学,临床数据和生物样本的纵向采集.
对前100名儿科新兵的自然史和临床特征进行分析.

主要成果:

首批100名IgAV患者的平均年龄为7.3岁,男性:女性比例为1.5:1.
23%的儿童在呈现时符合炎的定义,平均发病时间在疾病呈现后25.5天.
老年,富裕的住所,胃肠道干扰和呈现时阳性尿液测量棒增加了炎风险.
患有IgAV炎 (IgAV-N) 的儿童的住院次数和住院次数显著增加 (P < 0.001).

结论:

炎仍然是IgAV的严重并发症,强调需要更好的管理策略.
这项研究为开发试验准备的队列提供了一个典范,以推进IgAV研究.
需要进一步的研究来指导干预措施,并改善IgAV炎儿童的治疗结果.

关键词:

埃诺克·施恩莱因紫外线孩子们的孩子们的孩子们的孩子们.脏脏脏是什么?炎是一种神经炎症.儿科儿科儿科

更多相关视频

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

相关概念视频

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...